@article{b95e895eef3b4bc493b7192d3ffc4ad3,
title = "Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors",
keywords = "Covid-19, immunotherapy, metastatic triple-negative breast cancer",
author = "Patrizia Vici and Laura Pizzuti and Eriseld Krasniqi and Andrea Botticelli and Gennaro Ciliberto and Maddalena Barba",
note = "Funding Information: This work was supported by internal funding from the authors insitutions, in other words, Fondo unico sperimentazioni UOC OM2. V Patrizia received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili. P Laura, received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees from Roche, Pfizer, Novartis, Gentili. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = jul,
doi = "10.2217/imt-2020-0142",
language = "English",
volume = "12",
pages = "675--679",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "10",
}